US Food and Drug Administration Commissioner Scott Gottlieb has outlined plans for two new initiatives to modernize aspects of the generic drug review process.
Since his appointment as FDA chief, Dr Gottlieb has been vocal in his support for the generics sector, pledging to expedite development by addressing scientific and regulatory obstacles to competition.
The new plans, which will be funded by $37.6 million from the US President’s 2019 budget request, come on top of a series of initiatives to promote the development of generic medicines in the USA, including new active surveillance systems and a new process for submitting generic drug applications for review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze